Genmab(GMAB) - 2023 Q2 - Quarterly Report

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2023 August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights "The U.S. FDA approval of EPKINLY as the first bispecific antibody to treat adults with relapsed or refractory DLBCL was an important milestone both for Genmab and for patients in need of an innovative treatment option administered subcutaneously. We would like to thank the patients and investigators who took part in the EPCORE ...